Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$25.84
Change (%) Stock is Up 1.45 (5.95%)
Volume281,747
Data as of 04/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering (IPO) in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 70 employees.More >>

Recent NewsMore >>
DateTitle 
04/14/14Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal
Global, Pivotal Phase 3 APEX Study of Betrixaban Enrolling Acute Medically Ill Patients Using Biomarker-Based Strategy to Identify Those Most Likely to Benefit From Therapy SOUTH SAN FRANCISCO, Calif., April 14, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced publication of the design and rationale of the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in the March 2014 issue of the American Heart Journal.i Betrixaban, the... 
Printer Friendly Version
03/27/14Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban
SOUTH SAN FRANCISCO, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent, as a reversal agent for Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban in healthy volunteers. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidot... 
Printer Friendly Version
03/19/14Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
FDA-Designated Breakthrough Therapy is Portola's Second Drug to Enter Phase 3 Development SOUTH SAN FRANCISCO, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has initiated a Phase 3 study of andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.'s (NYSE: PFE) Factor Xa inhibitor Eliqui... 
Printer Friendly Version
03/18/14Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 18, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation. "We're thrilled to add John, a prestigious industry leader, to the Portola Board. John's strategic capabilities and his experience in oncology and biologics manufacturing will serve Portola... 
Printer Friendly Version
02/27/14Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2013. "2013 was a very successful year for Portola. We executed on a series of important milestones in pursuit of our goal of building an enduring biopharmaceutical company and bringing to market three wholly-owned and potentially grou... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.